Gaush Meditech Ltd, a Cayman-incorporated medical technology company listed in Hong Kong, disclosed its Monthly Return for Equity Issuer for the period ended 30 June 2026. Key data points are as follows:

• Authorised share capital was unchanged at 500.00 million ordinary shares with a par value of USD 0.0001 each, equivalent to total authorised capital of USD 50,000.

• Issued share capital remained stable at 147.89 million ordinary shares. The company held no treasury shares, and there were no new issues, cancellations, repurchases or redemptions during the month.

• No movements were recorded under share option schemes, warrants, convertible instruments or other equity-linked arrangements.

• Gaush Meditech confirmed that more than the required 25% public float threshold was maintained as at 30 June 2026, in line with Main Board Rule 13.32D(1).

• All regulatory confirmations required under Main Board Rule 13.25C were provided, with the return signed by Chairman and Executive Director Gao Tieta on 2 July 2026.

The absence of equity movements in June indicates a steady capital structure, while compliance with Hong Kong listing requirements underscores the issuer’s adherence to regulatory obligations.